← Leaderboards
Hillard M Lazarus
Case Western Reserve University
$3,198,402
Attributed
$3,524,736
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $283.6K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,524,736 · 4
By mechanism
U01$2,116,128 · 1
U10$754,774 · 1
R21$652,669 · 1
M01$1,165 · 1
Top collaborators
- Nora Singer4 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Raymond F Muzic$5,871,932
- Scott Michael Welford$5,685,124
- Robert D Harvey$7,816,864
- Nora Singer$3,497,199
- Samuel Rodgers-Melnick$97,232
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionClinical TrialsClinical ResearchImmuneRelapseTransplantationToxic EffectGraft-Vs-Host DiseaseRegimenRandomizedMalignant NeoplasmsPredispositionInvestigationProtocols DocumentationAllogenicCytokineHematopoieticInflammatoryPlacebosLifeT-LymphocyteBiological MarkersPreventAnti-Bacterial Agents
Grant awards (21)
Cell-based Therapy in RA: Proof of Concept$215,308
R21 · FY2018 · AR
Cell-based Therapy in RA: Proof of Concept$41,055
R21 · FY2018 · AR
Cell-based Therapy in RA: Proof of Concept$213,995
R21 · FY2017 · AR
Cell-based Therapy in RA: Proof of Concept$182,311
R21 · FY2016 · AR
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$146,419
U10 · FY2015 · HL · contact PI
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$146,836
U10 · FY2014 · HL · contact PI
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$147,200
U10 · FY2013 · HL · contact PI
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$147,649
U10 · FY2012 · HL · contact PI
Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT$166,670
U10 · FY2011 · HL · contact PI
NHLBI Blood /Marrow Transplant Clinical Research Network$115,244
U01 · FY2010 · HL · contact PI
NHLBI Blood /Marrow Transplant Clinical Research Network$115,244
U01 · FY2009 · HL · contact PI
NHLBI Blood /Marrow Transplant Clinical Research Network$115,244
U01 · FY2008 · HL · contact PI
NHLBI Blood /Marrow Transplant Clinical Research Network$1
U01 · FY2007 · HL · contact PI
NHLBI Blood /Marrow Transplant Clinical Research Network$155,000
U01 · FY2006 · HL · contact PI
Phase III Trial of UCB +/- MSCs in Hematologic Cancers$282,486
U01 · FY2005 · HL
ZOSUQUIDAR TRIHYDROCHLORIDE FOR ACUTE MYELOID LEUKEMIA AMP;REFRACTORY ANEMIA$1,110
M01 · FY2005 · RR
Phase III Trial of UCB +/- MSCs in Hematologic Cancers$390,310
U01 · FY2004 · HL
Zosuquidar trihydrochloride for acute myeloid leukemia &refractory anemia$55
M01 · FY2004 · RR
Phase III Trial of UCB +/- MSCs in Hematologic Cancers$389,323
U01 · FY2003 · HL
Phase III Trial of UCB +/- MSCs in Hematologic Cancers$148,276
U01 · FY2002 · HL
Phase III Trial of UCB +/- MSCs in Hematologic Cancers$405,000
U01 · FY2001 · HL